These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 29212909)
1. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. Juchem KW; Sacirbegovic F; Zhang C; Sharpe AH; Russell K; McNiff JM; Demetris AJ; Shlomchik MJ; Shlomchik WD J Immunol; 2018 Jan; 200(2):834-846. PubMed ID: 29212909 [TBL] [Abstract][Full Text] [Related]
2. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385 [TBL] [Abstract][Full Text] [Related]
3. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519 [TBL] [Abstract][Full Text] [Related]
4. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. Okiyama N; Katz SI J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812 [TBL] [Abstract][Full Text] [Related]
5. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Jones SC; Friedman TM; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296 [TBL] [Abstract][Full Text] [Related]
8. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925 [TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527 [TBL] [Abstract][Full Text] [Related]
10. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers. Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813 [TBL] [Abstract][Full Text] [Related]
11. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307 [TBL] [Abstract][Full Text] [Related]
12. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. Johnson BD; Becker EE; LaBelle JL; Truitt RL J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039 [TBL] [Abstract][Full Text] [Related]
13. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935 [TBL] [Abstract][Full Text] [Related]
14. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383 [TBL] [Abstract][Full Text] [Related]
15. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Johnson BD; Becker EE; Truitt RL Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958 [TBL] [Abstract][Full Text] [Related]
16. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Dutt S; Baker J; Kohrt HE; Kambham N; Sanyal M; Negrin RS; Strober S Blood; 2011 Mar; 117(11):3230-9. PubMed ID: 21239702 [TBL] [Abstract][Full Text] [Related]
17. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. Duffner UA; Maeda Y; Cooke KR; Reddy P; Ordemann R; Liu C; Ferrara JL; Teshima T J Immunol; 2004 Jun; 172(12):7393-8. PubMed ID: 15187116 [TBL] [Abstract][Full Text] [Related]
18. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Anderson BE; McNiff JM; Jain D; Blazar BR; Shlomchik WD; Shlomchik MJ Blood; 2005 Mar; 105(5):2227-34. PubMed ID: 15522961 [TBL] [Abstract][Full Text] [Related]
19. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 serves as a double agent in separating GVL from GVHD. Brennan TV; Yang Y J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]